GSK PLC
GSK: XLON (GBR)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
GBX 1,639.00 | Qhpc | Gzjqdjm |
GSK Earnings: Solid Results With Core Portfolio Offsetting Some Vaccine Headwinds
Despite vaccine challenges, GSK reported second-quarter results slightly ahead of our expectations but not enough to impact our fair value estimate. We continue to view the stock as undervalued, with the market not fully appreciating GSK’s growth potential and overly concerned about Zantac litigation that looks manageable.